On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Bristol Myers Squibb A Buy?
Bristol Myers Squibb stock is building a with a 61.08 entry. See if it can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The drug maker posted -10% earnings growth in its most recent report. Sales rose 8%.
Bristol Myers Squibb stock earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the top-ranked stock within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
